Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar-Apr;24(2):180-185.
doi: 10.4103/aja202188.

Neoadjuvant chemotherapy for patients with locally advanced penile cancer: an updated evidence

Xian-Yan-Ling Yi  1 , De-Hong Cao  1 , Ping-Hong You  2 , Xing-Yu Xiong  1 , Xiao-Nan Zheng  1 , Ge Peng  3 , Da-Zhou Liao  1 , Hong Li  1 , Lu Yang  1 , Jian-Zhong Ai  1
Affiliations

Neoadjuvant chemotherapy for patients with locally advanced penile cancer: an updated evidence

Xian-Yan-Ling Yi et al. Asian J Androl. 2022 Mar-Apr.

Abstract

Neoadjuvant chemotherapy (NAC) has shown promising results in patients with locally advanced penile cancer. However, no consensus exists on its applications for locally advanced penile cancer. Thus, it is unclear which kind of chemotherapy regimen is the best choice. Consequently, a systematic search of PubMed, Web of Science, and EMBASE was performed in March 2021 to assess the efficacy and safety of NAC for the treatment of patients with locally advanced penile cancer. The Newcastle-Ottawa Scale was used to assess the risk of bias in each study. This study synthesized 14 published studies. The study revealed that patients who achieved an objective response to NAC obtained a better survival outcome compared with those who did not achieve an objective response. In addition, the objective response rates (ORRs) and pathological complete response (pCR) rates were 0.57 and 0.11, respectively. The incidence of grade ≥3 toxicity was 0.36. Subgroup analysis found that the ORR and pCR of the taxane-platinum (TP) regimen group performed better than those of the nontaxane-platinum (NTP) regimen group (0.57 vs 0.54 and 0.14 vs 0.07, respectively). Moreover, the TP regimen group had more frequent toxicity than the NTP regimen group (0.41 vs 0.26). However, further studies were warranted to confirm the findings.

Keywords: chemotherapy regimen; locally advanced penile cancer; neoadjuvant chemotherapy; response rate.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure 1
Figure 1
Preferred Reporting Items for Systematic Reviews and Meta-analysis flowchart.
Figure 2
Figure 2
Forest plot of objective response rates for patients with advanced penile cancer followed by neoadjuvant chemotherapy. TP: taxane–platinum; NTP: nontaxane–platinum; ORR: objective response rate; CI: confidence interval.
Figure 3
Figure 3
Forest plot of pathological complete response rates for patients with advanced penile cancer followed by neoadjuvant chemotherapy. TP: taxane–platinum; NTP: nontaxane–platinum; pCR: pathological complete response; CI: confidence interval.
Figure 4
Figure 4
Forest plot of the (a) 2-year and (b) 5-year survival rates for the responder versus nonresponder group. M–H: Mantel–Haenzel; CI: confidence interval; df: degree of freedom.
Figure 5
Figure 5
Forest plot of the incidence of toxicity for patients with advanced penile cancer followed by neoadjuvant chemotherapy. TP: taxane–platinum; NTP: nontaxane–platinum; CI: confidence interval.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Hakenberg OW, Dräger DL, Erbersdobler A, Naumann CM, Jünemann KP, et al. The diagnosis and treatment of penile cancer. Dtsch Arztebl Int. 2018;115:646–52. - PMC - PubMed
    1. Howlader N, Ries LA, Stinchcomb DG, Edwards BK. The impact of underreported Veterans Affairs data on national cancer statistics: analysis using population-based SEER registries. J Natl Cancer Inst. 2009;101:533–6. - PMC - PubMed
    1. Misra S, Chaturvedi A, Misra NC. Penile carcinoma: a challenge for the developing world. Lancet Oncol. 2004;5:240–7. - PubMed
    1. Pham MN, Deal AM, Ferguson JE, 3rd, Wang Y, Smith AB, et al. Contemporary survival trends in penile cancer: results from the national cancer database. Urol Oncol. 2017;35:674.e1–9. - PubMed
    1. Philippou P, Shabbir M, Malone P, Nigam R, Muneer A, et al. Conservative surgery for squamous cell carcinoma of the penis: resection margins and long-term oncological control. J Urol. 2012;188:803–8. - PubMed